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Abstract: Overactive bladder (OAB) is a common condition which negatively impacts the 
quality of life of afflicted patients. This can result in alterations in social interactions at home, 
in the workplace and in the community, often leading to depression and poor self esteem as 
well as loss of productivity. Traditional mainstays of treatment include both behavioral therapy 
and pharmacotherapy. Oxybutynin immediate release (IR) represents the first such medication 
approved by the FDA specifically for treatment of OAB in 1975. Nevertheless, bothersome 
side effects in addition to thrice daily dosing often led to treatment cessation which raised the 
question that patients may actually prefer to live with their OAB symptoms rather than incur 
side effects or complex dosing schemes. Pharmacological advances ultimately led to develop-
ment of a long-acting formulation of oxybutynin in the form of oxybutynin extended release 
(ER) with the hope that this drug would maintain efficacy while decreasing bothersome side 
effects and improve compliance with the convenience of once daily dosing regimen. This paper 
will review the major clinical studies involving oxybutynin ER as well as its role in different 
patient populations and potential concerns with its use.
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Introduction
The International Continence Society defines overactive bladder (OAB) as: “Urgency, 
with or without urge incontinence, usually with frequency and nocturia in the absence 
of infection or any other proven causative pathology.”1 Thus the OAB population 
includes both patients with urge incontinence (OAB wet) as well as without urge 
incontinence (OAB dry). Indeed, the incidence of OAB dry has been reported at 66% of 
OAB patients while 33% have “OAB wet” and suffer from leakage.2 With prevalence 
rates similar to those of asthma and chronic bronchitis, the burden of this disease is 
enormous and presents great cost to society.3 The National Overactive Bladder Evalu-
ation (NOBLE) Program was a large scale, well designed epidemiological study which 
reported the prevalence of OAB in the US at approximately 16% with the distribution 
between men and women being roughly equal and with the prevalence mounting with 
increasing age.3 Similar results were seen in epidemiological studies in Europe with 
prevalence rates of OAB in the 12% to 17% range.4
The pathophysiology of OAB is not completely understood and likely there are 
multiple pathways leading to the end disease state. Normal bladder storage and micturition 
function requires precise neurologic and muscular coordination; possible alterations at the 
myogenic, mucosal and neurogenic levels may contribute to the condition. While caus-Drug Design, Development and Therapy 2009:3 152
Arisco et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
ative myogenic and mucosal alterations would take place at the 
end organ (bladder and urethra), adverse changes in bladder 
innervations may occur at the peripheral or central level. In such 
neurogenic theories, alterations in the neurologic pathways that 
normally provide tonic inhibition of detrusor contractions may 
account for the disease state.5 Alternatively, sensory nerve 
endings in the bladder may become hypersensitive, resulting 
in detrusor overactivity.5 Indeed, research studying the role 
of the urothelium in normal and abnormal micturitional states 
has advanced dramatically and shaped the field of OAB. It has 
long been understood that the autonomic nervous system 
plays a critical role in micturition. The sacral parasympathetic 
outflow provides excitatory input to the bladder via the pelvic 
nerve, which results in detrusor contraction. Bladder ganglia 
cells excite detrusor smooth muscle with release of both 
cholinergic neurotransmitter in the form of acetylcholine 
and also non-cholinergic, non-adrenergic neurotransmitters.5 
Acetylcholine activates muscarinic receptors on the detrusor 
smooth muscle and is considered a key neurotransmitter 
for detrusor function. There are 5 distinct subtypes of the 
muscarinic receptor throughout the body (M1-M5), the 
M2 and M3 sub-types predominating in the bladder. Although 
the density of M2 receptor is higher than the M3 receptor in the 
human bladder, M3 is thought to be more important in the 
manifestation of detrusor contractions.6 Given this basic 
understanding of neuroanatomy, it is not surprising that 
muscarinic cholinergic receptors became early therapeutic 
targets in OAB treatment.
Oxybutynin immediate release (IR) represents the first 
such medication approved by the FDA specifically for the 
treatment of OAB in 1975.7 It was originally investigated 
in the 1960s for the potential treatment of gastrointestinal   
hypermotility. Researchers incidentally discovered its 
usefulness as an agent for OAB and it has been since 
widely used for decades. In addition to its anticholinergics 
effects oxybutynin also shows some in vitro activity as a 
direct smooth muscle relaxant8 and early in vitro studies 
on rabbit detrusor also noted moderate local anesthetic 
action.9 Clinical efficacy for treatment of OAB symptoms 
was well documented in the 1990s.10 Despite proven efficacy, 
oxybutynin IR shows some major shortcomings as a therapeutic 
drug, namely high side effects, some so bothersome that some 
patients prefer to discontinue treatment and endure the disease 
itself rather than deal with the side effects. Lawrence et al 
showed a 6-month treatment adherence rate of only 32% in 
a retrospective analysis 515 patients prescribed oxybutynin 
IR in a pharmacy claims database.11 These pitfalls stem from 
fact that oxybutynin has a relatively nonspecific affinity for 
all of the various muscarinic receptors which are widespread 
throughout the human body. In addition to muscarinic 
receptors in the bladder, oxybutynin has particular affinity 
for muscarinic receptors in the central nervous system (CNS), 
gastrointestinal (GI) tract, parotid gland and eye which may 
account for troublesome cognitive impairment, constipation, 
dry mouth and difficulty with papillary accommodation. Of 
these, dry mouth appears to be most prominent, occurring in 
up to 80% of patients taking oxybutynin.12 Beyond bother, 
decreased salivation may predispose to oral infections and 
dental caries as well as inhibit proper mastication and swal-
lowing, particularly in the elderly.13,14
Given the limitations of oxybutynin IR, it comes as no 
surprise that alternative agents would be explored in the 
hopes that tolerability could be improved while maintaining 
efficacy in the treatment of OAB. Other antimuscarinics such 
as propantheline, methantheline, emepronium, dicyclomine, 
and terodiline were once employed as alternative OAB treat-
ment options as they were perceived to be more tolerable, 
however they were eventually abandoned due to either lack 
of efficacy and/ or poor tolerability.15,16 Currently, there are 
five different antimuscarinic drug formulations on the market 
for treatment of OAB in addition to oxybutynin. Tolterodine, 
propiverine, trospium, darifenacin and solifenacin all possess 
differing pharmacokinetic properties relating to organ and 
receptor subtype selectivities as well as structural differences. 
In addition, a separate strategy for changing the side effect 
profile of oxybutynin was employed by using an extended 
release (ER) formulation. In addition, a patch formulation 
of oxybutynin was developed in hopes that tolerability could 
be improved through of use of a different delivery system 
which altered drug metabolism and lengthened the drug 
dosing interval. An oxybutynin gel formulation was recently 
introduced into the US market with similar aims. In this 
article we focus our attention on oxybutynin ER formulation 
likewise meant to simplify drug dosing and improve on the 
side effect profile of the older oxybutynin IR.
History of oxybutynin ER
Oxybutynin ER came to market in the United States in 
199817 with intent to improve upon tolerability, convenience 
and compliance while maintaining efficacy by offering once 
daily dosing. OROS oxybutynin chloride (oxybutynin ER, 
Ditropan XL®) is an extended-release oral tablet formulation 
(OROS®) which utilizes osmotic pressure to deliver the drug 
at a controlled rate over 24 hours. The tablet itself consists 
of a semi-permeable membrane covering a drug layer which 
overlies an osmotically active “push” layer. In the GI tract, Drug Design, Development and Therapy 2009:3 153
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the absorption of water by this osmotically active layer results 
in the expulsion of the drug (which has likewise absorbed 
water forming a suspension) out a small opening in the 
membrane. Pharmacokinetic studies show that after the first 
dose of oxybutynin ER, plasma drug concentration rises for 
6 hours and then maintains a constant concentration for up to 
24 hours with steady state plasma concentrations achieved 
by day three of treatment.18 Normally, when absorbed in the 
upper GI tract, oxybutynin IR undergoes first pass metabolism 
by the cytochrome P450 system into its active metabolite 
N-desethyloxybutynin (NDO). This may be particularly impor-
tant as NDO has been proposed to be responsible for more dry 
mouth than oxybutynin itself.19 However, because the OROS 
system delays the release of oxybutynin in the ER formulation, 
it is thought that the parent drug is not biologically available 
until the tablet reaches the large intestine. By this point, the 
drug has bypassed the upper GI’s first pass metabolism system 
and is left to be absorbed in the colon where conversion to 
NDO is less likely and absorption is mainly of the parent drug 
itself. Biologically inert components of the tablet including the 
tablet itself are ultimately eliminated in the feces.
Early studies: extended release 
vs placebo and immediate release 
vs extended release
Early studies compared the effects of oxybutynin ER to 
placebo. The drug did show at least 40% greater decrease 
in urinary urge incontinence versus placebo in a 6-week 
trial though the results are recorded in abstract form only.20 
In an early industry sponsored study Anderson et al for the 
Ditropan Study Group enrolled 105 patients with urge incon-
tinence into a randomized, double blind study of dose titration 
to compare the efficacy and safety of controlled and imme-
diate release oxybutynin. They concluded that both groups 
shared a similar rate of reductions in urge incontinence and 
total incontinence episodes while the oxybutynin ER group 
reported significantly less dry mouth at 68% compared to 
87% for any degree of complaint.21 Another study published 
in the year 2000 sought to compare the efficacy and safety 
of oxybutynin IR as well as to determine rates of dry mouth. 
The authors enrolled known anticholinergic responders with 
seven or more urge incontinence episodes per week into a 
dose escalation trial of the IR and ER drug forms starting 
at 5 mg per day and increasing to 20 mg per day as limited 
by intolerable side effects. They likewise found comparable 
rates of reduction in incontinence episodes with similar rates 
of dose-dependent dry mouth, but moderate to severe dry 
mouth was significantly less prominent in the group receiving 
oxybutynin ER. Stratified by dosage, the greatest differences 
were at the 10 mg per day (8.5% for the ER group vs 25.6% 
for the IR group) and 15 mg per day doses (19.4% for the 
ER group vs 38.9% for the IR group) groups.22 Nevertheless, 
the early data on direct comparisons between oxybutynin IR 
and ER remain limited by trial design shortcomings including 
studying enriched populations such as known responders and 
reporting results on a “completer” basis. Some are reported 
only in abstract form at meetings and many are industry 
sponsored, thus limiting the ability to make evidence-ased 
conclusions of the two drug formulations.
In 2005 Dmochowski reported on the efficacy and safety 
of “individualized” doses of oxybutynin ER for urinary 
incontinence.23 His group combined data from three flexible-
dosing studies of patients with urge urinary incontinence 
or mixed incontinence; two of the data sets used were 
from trials completed in the late 1990s on ER versus IR 
oxybutynin while the third was from a study published in 
1999 by the Ditropan XL Study Group on “evaluation of a 
new once-daily formulation of oxybutynin for the treatment 
of urge urinary incontinence.”19,20,24 A total of 420 patients 
combined were assigned to treatment with oxybutynin 
ER. In the combined dataset, 420 patients were assigned 
to treatment with oxybutynin ER. Treatment began with 
5 mg daily of oxybutynin ER and was increased in 5-mg 
increments at intervals of approximately 1 week until the 
patient either achieved complete continence or experi-
enced intolerable side effects. Maximum dose was limited 
to 30 mg each day. The patients remained on maxiumum 
dose for 2 to 12 weeks according to which study they were 
participating in. Of these patients, some 14% had withdrawn 
prior to completion of their respective trial (some 6.7% due 
to adverse events), leaving 368 on drug at the end of the 
study periods. From the pooled data, 40% of these patients 
achieved total dryness with 80% sustaining 70% or better 
improvement in incontinence at their respective doses. Dry 
mouth was the most prevalent adverse event, but some ¾ 
of the studied patients experienced only mild or no dry 
mouth at all. The authors made note of the fact that 7% 
of the patients selected the dose of 30 mg per day with 
only slightly higher rates of dry mouth and similar rates of 
treatment discontinuation due to adverse events as subjects 
at lower daily doses. The authors freely acknowledge the 
limitations of post-hoc analysis of pooled data from studies 
that employed varying methodologies. In addition they 
recognize that the three studies each contained some of the 
previously discussed study design flaws common to early Drug Design, Development and Therapy 2009:3 154
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studies of oxybutynin ER versus IR, further weakening 
conclusions drawn in this paper.21
Oxybutynin ER vs other OAB 
medications
The next round of clinical trials involving oxybutynin mainly 
focused on comparison studies to other OAB medications. 
Two large, multi-center, prospective, randomized clinical 
trials comparing oxybutynin ER and tolterodine tartrate 
in OAB patients stand out for their sound methodology 
and power relative to all other clinical trials employing 
oxybutynin ER: the Overactive Bladder: Judging Effective 
Control and Treatment (OBJECT) Study25 and the Overac-
tive Bladder: Performance of Extended Release Agents 
(OPERA) trial.26
The OBJECT study was conducted between March and 
October 2000 at 37 US study sites with the objective to 
compare the efficacy and tolerability of fixed dose extended-
release oxybutynin and tolterodine tartrate at 12 weeks. The 
study enrolled and randomized 315 women and 63 men with 
overactive bladder who received either oxybutynin ER 10 mg 
daily or tolterodine tartrate 2 mg q 12 hours in a double-blind, 
double-dummy fashion. Trial completion was accomplished 
by 276 women and 56 men while a total 46 discontinued 
early, 29 because of adverse events (14 in the oxybutynin 
ER and 15 in the tolterodine group). Efficacy was assessed 
using self (diary) reported incontinence episodes as a primary 
outcome measure. The diaries documented number of voids 
as well as number and nature of incontinence episodes. Study 
findings included similar tolerability and discontinuation 
rates as well as similar adverse event rates for both drugs. 
In the OBJECT Study, oxybutynin ER proved significantly 
more effective than tolterodine in reducing the mean number 
of weekly urge incontinence episodes at end of study as well 
as total incontinence episodes and total urinary frequency. 
Urge incontinence episodes improved from 25.6 ± 14.7 to 
6.1 ± 9.7 for oxybutynin ER and 24.1 ± 14.5 to 7.8 ± 11.1 for 
tolterodine. Total number of incontinence episodes per week 
decreased from 28.6 ± 17.9 to 7.1 ± 12 for oxybutynin ER 
and from 27 ± 17 to 9.3 ± 13.4 for tolterodine. Micturitions 
per week decreased from 91.8 ± 22.6 to 67.1 ± 22.1 for 
oxybutynin ER and from 91.6 ± 20.2 to 71.5 ± 20.5 for 
tolterodine. Both drugs significantly improved all studied 
outcome parameters. The authors made note of the limited 
applicability of 12 week results with regards to a chronic 
condition such as OAB. They also noted that the study popu-
lation was selected by specialists rather than primary care 
physicians who treat most OAB and that study population 
was not racially diverse, though this is a common limitation in 
most OAB studies. It should be noted that OBJECT compared 
once daily oxybutynin ER to twice daily tolterodine tartrate, 
though this formulation of tolterodine has essentially been 
replaced in most cases by the once daily formulation of tolt-
erodine which is expected to improve patient compliance. 
Regardless, OBJECT did compare oxybutynin ER with the 
most widely prescribed non-generic anticholinergic medica-
tion at that time in a blinded head to head randomized clinical 
trial in the US.23
It must be noted that the OBJECT study was funded by 
ALZA Corporation in Mountain View, California, a bio-
pharmaceutical company with specialization in drug delivery 
systems and developer of the OROS drug delivery system. 
The authors include advisors, investigators and speakers for 
ALZA Corporation as well as one employee stockholder of 
ALZA Corporation.
The second large multicenter trial, OPERA, was likewise 
funded by the ALZA Corporation as well as Ortho-McNeil 
Pharmaceutical in Raritan, NJ, makers of oxybutynin ER. 
OPERA authors likewise disclosed relationships including: 
medical consultant, investigator, advisor as well as an 
employee and stockholder of Ortho-McNeil and an employee 
and stockholder of AZLA.
The OPERA Trial sought to compare the efficacy and 
tolerability of extended-release formulations of both oxy-
butynin chloride and tolterodine tartrate in women with 
overactive bladder. The trial ran from November 2000 to 
October 2001 and pitted oxybutynin ER head to head with the 
most prescribed once daily anticholinergic in a prospective, 
randomized, double-blind study conducted at 71 US centers. 
US women aged 18 years or older who documented 21 to 
60 episodes of urinary urge incontinence per week and an 
average of 10 or more voids per 24 hours were recruited. 
A total of 790 women were randomized to receive either 
10 mg of oxybutynin ER or 4 mg of tolterodine ER per day. 
Randomized groups were similar in both demographics and 
severity of OAB while prior treatment for OAB was not 
an exclusion criteria. Patients kept 24-hour voiding diaries 
at baseline and during weeks 2, 4, 8 and 12 of treatment. 
Outcome measures were reduction from baseline in the 
number of urinary urge incontinent episodes/week, weekly 
total incontinence episodes and weekly micturition frequency 
numbers. A similar number of patients completed the study 
in both groups (87% for the oxybutynin ER group versus 
89% for the tolterodine ER group.) Likewise, rates of discon-
tinuation due to adverse events were essentially equal with 
20 oxybutynin patients and 19 tolterodine ER patients.Drug Design, Development and Therapy 2009:3 157
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There was no statistical difference in the number of 
weekly urge incontinent episodes at the end of study for the 
competing groups. After 12 weeks of treatment, the oxybu-
tynin ER group saw a reduction from a mean of 37.1 to 10.8 
urge incontinent episodes per week while the tolterodine ER 
group dropped from 36.7 to 11.2. The oxybutynin ER group 
performed slightly for reducing total mean number of weekly 
incontinent episodes and weekly micturition frequency. 
This was statistically significant for the number of micturi-
tion episodes per week. For total incontinent episodes per 
week, the oxybutynin group went from 43.4 to 12.3 and the 
tolterodine group from 42.4 to 13.8. Total decrease in mean 
number of voids per week was 28.4 for the oxybutynin group 
versus 25.2 for the tolterodine group; respective means were 
66.4 and 71.7 at the end of 12 weeks treatment. Slightly more 
patients in the oxybutynin ER group reported no incontinence 
episodes in their final diary versus the tolterodine ER group 
at 23% versus 16.8% completely dry. Dry mouth was more 
common in the oxybutynin ER group at 29.7% versus 22.3% 
in the tolterodine group; while statistically significant, the 
majority of the dry mouth effects were categorized as mild 
(93% of oxybutynin ER participants and 95% of tolterodine 
ER participants.24
Overall, the OPERA study shows oxybutynin ER to 
have modestly greater efficacy than ER tolterodine at its 
most commonly prescribed dose. The authors point out 
that the flexible dosing allowed for oxybutynin provides a 
wider range of FDA approved dosages allowing individuals 
to balance their respective efficacy and tolerability without 
turning to off label dosages as would be required with 
tolterodine ER of 4 mg daily. One obvious limitation of the 
OPERA study is its study population of women only. While 
women do constitute the majority of patients presenting with 
complaints of overactive bladder, the condition is certainly 
not limited to women. Some epidemiological studies would 
argue that the prevalence in men is nearly equal.3
In 2006, Anderson et al published a post hoc analysis 
of data from the OPERA trial specifically comparing the 
efficacy and tolerability of oxybutynin ER and tolterodine 
ER in women with or without prior anticholinergic treatment 
for OAB. They found that oxybutynin ER was significantly 
more effective in reducing micturition frequency by week 12 
among the population of patients with prior anti-cholinergic 
treatment experience. Likewise in this particular subgroup, 
the participants taking oxybutynin ER reported a statistically 
significant greater chance of being incontinence free and 
they had a greater reduction in number of urge incontinence 
episodes. In contrast, the anticholinergic-naive group showed 
statistically equal efficacy for all study parameters with the 
exception of average number of micturitions per week at 
study completion; this parameter favored the participants 
taking oxybutynin ER. Dry mouth was more common in the 
oxybutynin ER study participants, but only in the group with 
history of prior anticholinergic treatment.27
Special populations and other trials
Several clinical trials address the use of oxybutynin ER in 
special populations, including the elderly, children, and 
neurogenic bladder. Interestingly, while the concept that 
OAB may contribute to male lower urinary tract symptoms 
has become more widely accepted28 we were unable to 
identify any studies in the literature focusing on oxybutynin 
ER in the male subpopulation. Oxybutynin ER is considered: 
“Pregnancy Catetory B,” reproduction studies in the mouse, 
rat, hamster and rabbit showing no definite evidence of 
impaired fertility or harm to animal fetus. According to the 
manufacturer’s package insert: “The safety of Ditropan XL 
administration to women who are or may become pregnant 
has not been established. Therefore Ditropan XL should 
not be given to pregnant women unless, in the judgement 
of the physician, the probable clinical benefits outweigh the 
possible hazards.” It is unlikely that studies of oxybutynin 
in pregnant women will ever be undertaken.
The elderly represent a special population in OAB treat-
ment particularly related to risk of negative effects on the 
CNS such as cognitive impairment and memory problems. 
They tend to be at risk for poly-pharmacy, often taking a 
variety of medicines besides anticholinergics which may 
also have adverse effects on the CNS. As the number of 
medications use increases, so does the risk to the older patient 
including problems with compliance as well as potential 
drug-drug interactions which can cause adverse events or 
alter drug efficacy.29 Older patients are at risk for falls and 
sleep disturbances, and they often already suffer from dry 
mouth, dry eye, and vision problems as well as GI motility 
problems including constipation.30
Kay et al studied the differential effects oxybutynin ER 
versus the drug darifenacin on memory in older patients. In a 
multicenter, double blind study, 150 healthy individuals over 
the age of 60 with OAB were randomized to receive oxybu-
tynin ER, darifenacin or placebo. Initial dose for oxybutynin 
ER was 10mg daily, and increases in 5-mg increments was 
permitted up to 20 mg by the end of this 3-week study. 
Initial dose for darifenacin was 7.5 mg each day for 2 weeks, 
with permitted increase to 15 mg each day for the final 
week. Primary outcome was the effect of each antimuscarinic Drug Design, Development and Therapy 2009:3 158
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versus placebo at 3 weeks on recent memory as measured by 
the delayed recall Name-Face Association Test. Secondary 
end points included delayed recall on the First-Last Name 
Association Test and the Misplaced Objects test. Results of 
this study showed that oxybutynin ER caused significant 
memory deterioration, while darifenacin did not cause 
memory changes significantly different from placebo. While 
oxybutynin ER may be FDA approved to 30 mg daily dose, 
the most commonly prescribed dosage is 10mg daily which 
is the same dose selected for OBJECT and OPERA trials. 
Despite this potential dosage mismatch, interval evaluation 
of study subjects does show a drop in measured cognitive 
function in the oxybutynin ER group after one week even at 
10 mg daily. Despite the short duration of the study, it does 
show that older patients with pharmacological steady state 
plasma levels of oxybutynin ER may have an increased risk 
of impaired cognitive function relative to those in steady 
state taking darifenacin.31
Contrary to the relatively high dose oxybutynin ER used 
in previous study, Lackner reported a randomized, placebo-
controlled trial of the cognitive effect, safety and tolerability 
of 5mg daily dosage of oxybutynin ER in a population of 
cognitively impaired nursing home residents with urge 
incontinence. The authors cite that OAB is undertreated 
in this population due to the fear that the frail older patient 
is more susceptible to anticholinergic associated adverse 
reactions. They note the lack of studies to document safety 
and efficacy of anticholinergics in the frail elderly population 
despite the high prevalence of urinary urge incontinence in 
particular. In this trial, 50 women aged 65 and older with 
urge incontinence and documented cognitive impairment 
were randomized to oxybutynin ER versus placebo and 
followed closely for 4 weeks. Primary outcome measures 
included the Confusion Assessment Method (CAM,) an 
accepted, validated and widely used diagnostic algorithm 
to measure cognitive function. Changes in CAM score from 
baseline were the primary outcome with presence or absence 
of delirium as determined by the CAM. Other secondary end-
points were further standardized measurements of cognition. 
In short, the study showed that oxybutynin ER 5 mg daily 
was well tolerated in elderly female nursing home patients 
with mild to severe dementia. There was no significant 
impairment in cognitive function in the treatment group by 
any measured outcome at any measured point in the study. 
There were no more withdrawals in the treatment versus 
placebo groups nor was there any difference in adverse 
events. Forty seven participants completed the study, 96% 
on drug versus 92% receiving placebo. Rates of agitation and 
falls were equal with 54% of the participants in both groups 
experiencing at least one fall during the months preceding, 
including and following the trial. Study limitations include 
the short duration, homogenous Caucasian female population 
as well as lack of information about efficacy at this dosage.32 
However, these results do contradict the guidelines of the 
American Neurological Association, the American Psychi-
atric Association and the Beers Criteria for Potentially Inap-
propriate Medication Use in Older Adults33 and conclusions 
about their use in this population remain guarded.
CNS side effects do represent a cause of potential 
severe consequences in the elderly in particular. Current US 
prescribing information applying to all forms of oxybutynin 
states under precautions: “A variety of CNS effects have 
been reported including hallucinations, agitation, confusion 
and somnolence. Patients should be monitored for signs of 
anticholinergic CNS effects, particularly in the first few 
months after beginning treatment or increasing the dose.” 
It also cautions that the drug “should be used with caution 
in patients with pre-existing dementia treated with cholin-
esterase inhibitors due to risk of aggravation of symptoms” 
and that the drug “should be used with caution in the frail 
elderly.”
Children represent another highly unique “special” 
population to consider when considering drug therapy. 
Drug treatment of neurologically intact children with OAB 
type symptoms generally focuses on incontinence, which 
can, in older children have marked effects on the child’s 
social and psychological development and well being in 
addition to causing great stress and anxiety in parents. 
Beyond behavioral therapy and biofeedback, clinicians, 
parents and patients often wish to turn to drug therapy to 
treat OAB. While studies on OAB drugs in adults are limited 
and conflicting, there are, simply put, very few studies in 
children. Only one non-randomized clinical study was iden-
tified investigating therapeutic efficacy and tolerability of 
oxybutynin ER in children. The authors identified 86 girls 
and 46 boys between the ages of 5 and 18 years of age who 
were referred to a pediatric urology clinic with diurnal 
urinary incontinence and OAB symptoms including urinary 
frequency, urgency, posturing associated with urge and/or 
spontaneous urinary incontinence. These children were 
arbitrarily assigned to receive tolterodine IR, tolterodine ER 
or oxybutynin ER based primarily on the formulary restric-
tions of their health care plans. Medications were started at 
the lowest dose available in non-liquid form (tolterodine IR 
and ER at 2 mg, oxybutynin ER 2 mg) and titrated according 
to response and tolerability. After thorough baseline Drug Design, Development and Therapy 2009:3 159
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evaluations, study nurses assessed efficacy by voiding diary 
and side effects on the basis of direct questioning to parents 
and patients. Validated instruments were not used and it 
appears that assessments did not occur at set, prescribed 
points in time. In 2003 the authors reported their retro-
spective analysis citing that all medications appeared well 
tolerated and that the ER formulations of both oxybutynin 
and tolterodine were significantly more effective than IR 
tolterodine. Oxybutynin ER was again significantly more 
effective than either formulation of tolterodine for control 
of daytime urinary incontinence and micturition frequency.34 
While this non-randomized, non-blinded retrospective study 
using non-validated instruments contains serious flaws, it 
nevertheless represents the very small amount of literature 
devoted to use of oxybutynin ER in children and suggests 
that the use of this type of medication is safe and effective 
in children and that oxybutynin ER is at least as effective 
as either formulation of tolterodine.
One other study focused on the use of oxybutynin ER in 
children with neurogenic bladder (NGB). This is a distinct 
and important subset of patients who frequently require 
aggressive management of bladder issues to maximize social 
functionality as well as to protect renal function. While 
published studies as early as 1977 address the use of oxybu-
tynin IR in this population, very little is available regarding 
oxybutynin ER in children with NGB.35 Interestingly, no 
studies were identified which reported specifically on use 
of oxybutynin ER in adults with neurogenic bladder. Franco 
et al reported on use of three different formulations of oxybu-
tynin in children aged 6–15 years of age who performed clean 
intermittent catheterization (CIC) and who had documented 
neurogenic detrusor overactivity at 24 different centers in the 
US and Europe. Sixty one patients received oxybutynin ER 
while 28 received oxybutynin IR and 30 were treated with 
oxybutynin syrup. Efficacy and tolerability were assessed 
at 24 weeks. Improvement of urodynamic parameters was 
seen in all treatment arms as well as increased continence. 
Likewise all three drug formulations were well tolerated 
and no patient discontinued treatment due to adverse events 
related to oxybutynin. In contrast to other studies, constipa-
tion represented the most frequently reported adverse event 
in this population while dry mouth is not even listed as occur-
ring at 5%.36 Despite flaws, this report does provide some 
evidence for tolerability of oxybutynin ER in this small but 
important patient population.
Finally we consider the issue of cost related to OAB 
and oxybutynin ER. First, one must understand the stagger-
ing financial cost of OAB in modern society; estimates of 
dollars spent annually in the US alone run to US$12 billion.37 
While non-pharmacological treatment methods may be 
employed, anticholinergic medications represent the mainstay 
of treatment for OAB and drug costs contribute consider-
ably to the overall burden of cost related to OAB. However, 
some studies do indicate that drug therapy for OAB may 
be associated with decreased utilization of other healthcare 
resources resulting in cost savings elsewhere;38 naturally, 
the cost of therapeutic medication for OAB may offset these 
net savings. Considerable literature in the managed care and 
pharmacoeconomics literature is devoted to these issues 
including evaluations of oxybutynin ER as a therapeutic 
choice for OAB. The economic modeling is quite complex 
and unique in each case due to the regional or geographic 
variation with myriads of variables affecting cost of treatment 
and cost of disease state. One European study sought to study 
the cost-effectiveness of long-term pharmacological manage-
ment of urge urinary incontinence using IR oxybutynin and 
tolterodine as well as ER formulations of the two drugs in 
the United Kingdom. The study included estimated costs of 
incontinence products such as pads which are often paid out 
of pocket in the US and often overlooked. They concluded 
that tolterodine IR was less cost effective than the other 
three drug choices.39 In contrast, two large US retrospec-
tive studies designed to determine financial cost and benefit 
of treatment with ER formulations of oxybutynin versus 
tolterodine estimated healthcare costs based on reimburse-
ment for services (hence only covered benefits) by using 
enormous patient databases related to US health insurers.40,41 
Both studies found cost savings in total reimbursement costs 
over one year for patients treated with tolterodine ER versus 
oxybutynin ER.
Conclusions
Antimuscarinic agents remain a mainstay of therapy for the 
treatment of OAB. While this medication class has proven 
efficacious for this condition, decreased tolerability due to 
antimuscarinic side effects remains a major problem limiting 
its acceptance. Oxybutynin has proven to be effective for the 
treatment of OAB however antimuscarinic side effects such as 
dry mouth and constipation often limit patients’ compliance 
with it. The use of the OROS delayed release delivery system 
is an excellent example of how altering the delivery of the 
active agent can improve oxybutynin’s tolerability while 
still maintaining its effectiveness. This transformation has 
allowed oxybutynin to remain a formidable treatment option 
for OAB despite the introduction of newer and more tissue-
specific antimuscarinic agents.Drug Design, Development and Therapy 2009:3 160
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Oxybutynin ER has clearly demonstrated its applicability 
in the treatment of OAB and voiding dysfunction in the 
adult population. Oxybutynin IR has been widely used in 
the pediatric population for neurogenic bladder and voiding 
dysfunction though there are limited studies looking at the 
oxybutynin ER formulation in children. The use of oxybutynin 
in the elderly remains a concern and treatment dilemma. The 
incidence of OAB and urinary incontinence increases with age 
yet the use of oxybutynin in this population is cautioned due to 
concerns that older patients may have problems with increased 
side effects especially for CNS, memory and cognition. These 
concerns warrant further investigation.
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